{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-22-000054","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.626221+00:00","generated_at":"2026-06-22T09:23:29.045709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Keros Q3 net loss $23.5M; cash runway extended to Q1 2025","bullets":["Net loss of $23.5M in Q3 2022 vs $20.3M in Q3 2021, driven by higher R&D and G&A costs.","R&D expenses $21.0M (+$6.2M YoY); G&A expenses $6.9M (+$1.6M YoY).","Cash and cash equivalents $239.4M at Sep 30, 2022; ATM proceeds extend runway into Q1 2025.","KER-012 Phase 1 data presented; Phase 2 PAH trial design expected early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-22-000054","json":"https://secwatch.observer/filing/0001664710-22-000054.json","markdown":"https://secwatch.observer/filing/0001664710-22-000054.md","text":"https://secwatch.observer/filing/0001664710-22-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471022000054/0001664710-22-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471022000054/kros-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:23:29.045709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb0a9d9ff8b89334ec36fe18e321ebc72845a370","claim":"Keros Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income net loss of $23.5 million.","evidence_excerpt":"Keros reported a net loss of $23.5 million in the third quarter of 2022 as compared to a net loss of $20.3 million in the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471022000054/0001664710-22-000054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"net loss of $23.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}